1、9 January 2024JPM 2024Gordon Sanghera,CEO 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.DisclaimerThis presentation has been prepared by Oxford Nanopore

2、 Technologies plc(“Oxford Nanopore”)for information purposes only and does not constitute an offer of,or solicitation to purchase or subscribe for,any securities in which such offer or solicitation is unlawful or to any person to whom it is unlawful to make such offer or solicitation.Investors and p

3、rospective investors in the securities of Oxford Nanopore are required to make their own independent investigation and appraisal of the business and financial condition of Oxford Nanopore and consult their own independent financial,legal,tax and business advisors.The information contained in this pr

4、esentation has been provided by Oxford Nanopore and other sources identified therein for the exclusive use of the intended recipient and is highly confidential.No information provided as part of this presentation may be used,copied,reproduced,in whole or part,or otherwise disseminated,directly or in

5、directly,by any recipient to any other person.To the extent permitted by applicable law,no representation or warranty,express or implied,is made by Oxford Nanopore or any member,employee,officer,director,representative,agent or affiliate of Oxford Nanopore as to the accuracy or completeness of any i

6、nformation contained in this presentation.Oxford Nanopore expressly disclaims any and all liability that may be based on any information contained in this presentation and any errors or omissions herein.Oxford Nanopore products are not intended for use for health assessment or to diagnose,treat,miti

7、gate,cure or prevent any disease or condition.This presentation and the discussion which follows it may contain statements that are forward-looking.For example,statements regarding expected revenue growth and profit margins are forward-looking statements.Phrases such as aim,plan,“expect”,intend,anti

8、cipate,believe,estimate,target,and similar expressions of a future or forward-looking nature should also be considered forward-looking statements.Forward-looking statements address our expected future business and financial performance and financial condition,and by definition address matters that a

9、re,to different degrees,uncertain.Our results could be affected by macroeconomic conditions,the COVID-19 pandemic,delays in our receipt of components or our delivery of products to our customers,suspensions of large projects and/or acceleration of large products or accelerated adoption of pathogen s

10、urveillance.These or other uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements.2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,tre

11、at,mitigate,cure,or prevent any disease or condition.Oxford Nanopore Technologies(ONT)Single molecule sensing platformHighly differentiated sensing platform:initial application in DNA/RNA sequencing Sustainable,agile innovationDelivering new products and evergreen IP portfolio with 2,500 patents and

12、 patent applicationsMarket Opportunity$6.21 billion,growing existing opportunity with potential$150bn in future clinical and applied marketsExpanding Customer BaseScientific Research customers expanding to now include clinical MinION Launched 2015.Today 7,300 customers in 120 countries,with 8,800 pu

13、blications since launch.Scaled operationsIn-house manufacturing facility opened 2018 with capacity to meet growth over next 5 yearsOur peopleFounder leadership with 1,200 employees worldwideOxford Nanopore formed 2005 to develop a new sensing platform1 Source:DeciBio.2024 Oxford Nanopore Technologie

14、s plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Oxford Nanopore financial performance32.5m52.1m65.5m127.0m146.8m169m2002120222023EFY23 preliminary numbersLSRT revenue169mUnder

15、lying revenue growth39%Cash,cash equivalents and liquid investments467mRevenue accountedfor by consumables75%Oxford Nanopore ONT Listed on LSE Oct 2021 Underlying revenue is LSRT revenue growth excluding revenue from the Emirati Genome Program and COVID sequencing 2024 Oxford Nanopore Technologies p

16、lc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Medium to long-term targets Medium term(FY26)Financial GuidanceDisruptive innovationCommercial operations30%Underlying LSRT revenue growth10-

17、20%of LSRT revenue from clinical and applied industrial markets65%LSRT gross marginAdjusted EBITDAbreakeven by the end of 2026Sample to answer workflows Q Line products designed for regulated and applied marketsNanopore protein sensing in developmentPath to productise voltage sensingExpand geographi

18、cal footprint directlyor through channel partnersKey,senior hires to drive growth in key markets and S3 customer groupUpgrade all digital platforms to offer best-in-class customer experienceScale our global operations to meet growing demand 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Techn

19、ologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.DNA is the source code of all living things MetagenomeMixed speciesVirusEg Influenza A8 segments of RNA 13.5KbCropEg wheat17Gb x 6Human3Gb x 2MammalEg cow 3Gb x 2(3

20、billion base pairs x 2)BacteriaEg E.coli4.6Mb(4.6 million base pairs)What is it?What is in it?Is it healthy or diseased?Is it harmful?Is it changing?Responding?What is the disease?How does it vary from others?2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intende

21、d for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Central Dogma of BiologyNanopore MultiomicsLegacy Multiomics$and complexand is the source code of biological functionBeyond DNA,Oxford Nanopore is changing the meaning of multiomicsDNAGenomics:SNV

22、SVEpigeneticsFragmentomicsRNATranscriptomics:Gene expressionIsoformspolyA tail lengthModifications PROTEINProteomics:Protein levelsSequencePost-translational modsSBS MicroarrayBisulfiteRNA-Seq Deep RNA-Seq PSIRACE-PATMeRIP-seq/CLIPImmunoassayHPLC or MSMeRIP-seq/CLIPNanopore native DNA sequencingDire

23、ct RNADirect peptideand amino aciddetectionFull-lengthcDNA 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Our JourneyStrong technology foundationsPowerin

24、g todays productsand future onesAxopatch1 Channel1 Nanopore channel1 experiment per person per weekMinION512 Channels512 channels per flow cellPromethION P48128,400 Channels2675 channels per flow cell200520142019Voltage Sensing10,000 100,000 Channels per flow cellPotential for 1-hour genomesMultiomi

25、csDNA,RNA,PHASINGEPIGENETICSFRAGMENTOMICSPROTEINSSMALL MOLECULESOne platformFlongleMinIONGridIONPromethION 2PromethION 24/48Foundational IP:Oxford|Harvard|UCSC|Texas A&M|UMass|VIBMore than 2,500:ONT-assigned&in-licensedgranted patents and applications32 Licence agreements in evergreen IP PortfolioMo

26、re than 1,000:Patents filed since 2016 with evergreen portfolio 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Nanopore Sequencing6 key components01.MOTO

27、R02.NANOPORE03.RUN CONDITIONS(Salt,fuel,software)04.MEMBRANE05.BASECALLER06.ASIC(MinION,PromethION,Flongle)126 channels512 channels2,675 channelsNanopore Sequencing Highly Differentiated Sensing TechnologyThree types of flow cells with 100s to 1000s of individual nanopore channelsCustomers prepare s

28、amples with our range of fast and simple library preparation kits(time from 10 minutes)DNA is pulled into the nanopore at 400 bases per second“Translocation”produces raw signal streamed in real time to on board computeMachine Learning/AI models decode signal into bases onboard devices.No additional

29、compute requiredBasecalled data is analysed by users own pipelines or by pre-prepared informatics pipelines on EPI2ME 2024 Oxford Nanopore Technologies plc Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease o

30、r condition.Rapid development of EPI2ME,our cloud and local informatics softwareReal time basecalling and analysisHighly accelerated ML/AI algorithms with latest software releaseMinION:Apple M1 max or M2 maxReal-time Q20 basecalling of 1 MinION Flow Cell PromethION:A SeriesReal-time Q20 basecalling

31、of 48 PromethION Flow CellsGridION:GV100Real-time Q20 basecalling of 5 MinION Flow Cells EPI2ME now with 3rd party analysis integration 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or pre

32、vent any disease or condition.Nanopore accuracy todayComplete genomic information from a single run 99.3%Simplex99.7%Variant calling99.84%Simplex withimproved enzyme99.9%DuplexQ40+“T2T”Human ConsensusQ50+“T2T”Human consensus with 5b4 Tenured&tenacious R&D group continuously improving performanceGeno

33、me browser screenshot of a human sample(NA02533)with Mucolipidosis type IV,characterised by a missense SNP in position 7,526,759 and a deletion of 6,433 bp(txStart-exon 7).Accuracy reported here have been calculated for 30X coverage,basecalling with the high accuracy model(HAC).In field todayIn deve

34、lopmentEpigenetic variation99.6%accuracySV calling 96.1%accuracyPhasingMegabase-scaleSNV calling99.7%accuracy“Using a single PromethION Flow Cell,we can detect SNPs with F1-score better thanshort-read sequencing”.Kolmogorov et al.,2023 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologi

35、es products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Small variantsSNPs and INDELs well characterised by existing technology.E.g.Sickle cell disease and cystic fibrosisLarger,more complex variantsStructural variants includi

36、ng Copy Number Variants,Repeats,Expansions only fully visible with the advent of long reads.E.g.alzheimers,ParkinsonsEpigeneticsMethylation,highly involved in complex disease,e.g.cancer,is only partially visible through modified chemistries or algorithmic interpretations is now unlocked with native

37、nanopore sensingDark genomeMedically important areas of the genome that have only recently been uncovered and only visible through native DNA or RNA sequencingWe can finally uncover all areas of the genome 2024 Oxford Nanopore Technologies plc Oxford Nanopore Technologies products are not intended f

38、or use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.DNA Se

39、quencing has been in a Mainframe momentNanopore sequencing technology enables real-time,affordable,accessible and high performance,in small to high throughput formats.2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diag

40、nose,treat,mitigate,cure,or prevent any disease or condition.Our fully scaled platformFrom small handheld to flexible high-capacity systems all highly affordable through our OpEx ModelsMinION2 FCs&1 KitsPromethION P2 solo 8 FCs&2 KitsFrom$1,999From$9,555GridION96 FCs&16 KitsPromethION P2(i)96 FCs&16

41、 KitsFrom$89,000From$125,000PromethION P24512 FCs&XL KitsPromethION P481,246 FCs&XL KitsFrom$495,000From$950,000Personal SequencersScale-up SequencersHigh Throughput Sequencers 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment

42、or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Our business modelWith sequencers from only$1,000,Nanopore sell to users who dont perform sequencing today.More than 80%of orders are placed without interaction from the sales and support teams.Users learn to use devices through

43、online resources or booking a lab call.GridION and PromethION P2(i),P24 and P48 are sold and supported by a field-based sales and support team.Taking market share through unique features and benefits.Seed the market with affordable starter packsExpand the market with self-service MinION and P2 Solo

44、user baseTake market share with classic“B2B approachMost of the“sequencing hardware”is in the consumable flow cell enabling:Simple,affordable sequencing devicesRapid platform iterations deployed in consumable upgradesHigher margins with 75%of revenue generated by consumable salesOur flow cells are o

45、ur sequencers 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Our customersCommercial resources to fit customer types“genomic explorers”“expanding everyda

46、y sequencing”“multi-installation customers”S1S2S3Under$25,000$25,000$250,000$250,000 2024 Oxford Nanopore Technologies plc Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.100200*300*400*20,000

47、15,00010,0005,0004,0003,0002,0001,000500014,97619,968Human genome sequencing capacity1/year2084166242,4964,9924,9929,9847.4888329,984Gigabase/flowcell*Future chemistries*Assumes 30 x WHG at Q20 accuracyEnzyme speed and blocking are two key drivers of output,both highly active R&D programmesPrice per

48、 genome*$690Price per genome*$345Price per genome*$235Price per genome*3,600 Icelandic individuals2022DNA methylation in cancer liquid biopsies2018Longest sequencingread(2Mb)2020First complete human chromosome(X)sequence2021In-surgery brain tumour classification2022First monkeypox genome2022Method o

49、f the Year:Long-read sequencing2016Real-time,portableEbola outbreaksurveillance2021Largest animal genome assembled:43 GbLungfish genome20223-hour newborn sequencing2022High school student first to sequence Angelfish genome2020First SARS-CoV-2genome2021Low-coverage,portable genotyping2022Complete hum

50、an genome2022eDNA sequencing for Kkp conservation2023Nanopore sequencing for Mycobacterium tuberculosis drug susceptibility testing and outbreak investigation:a genomic analysis2023Exploring structural variation in underlying breast cancer susceptibility2023Scalable Nanopore sequencing of human geno

51、mes provides a comprehensive view of haplotype-resolved variation and methylation2019Human transcriptome analysis with direct RNA20191-day turnaround for microbial identification in respiratory tract infections2017DNA methylation detection using nanopore sequencing2023Nanopore only single cell and s

52、patial2020Community advances in adaptive sampling algorithmsCelebrating scientific advances published by the Nanopore Community 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any

53、 disease or condition.Priority research applications act as foundation for emerging clinical applicationsHumanHigh Throughput WGS atScale from High-N-to-PopGenCancerCancer Research&Immuno-Oncology ApplicationsInfectiousViral,Microbial,Infectious&Synthetic GenomesTechnology ApplicationsIndustry Secto

54、rsCommercial ChannelsSingle CellMethylationEmergingBioPharmaClinical LabsAgBioDirectDistributorsCSPsCore Labs?Translated to our core commercial focus areas 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,

55、mitigate,cure,or prevent any disease or condition.Reflected by the breadth of applications from our customersFrom rapid WGS to liquid biopsy and beyond“Genetic tests just arent thought of as tests that come back quickly.But were changing that perception”DNA to 60 x genome in$150 billion in 2032Clini

56、cal opportunitiesEg.Human genetics,cancer,infectious disease1Source:DeciBio.Sequencing consumables and devices.Excludes servicesRESEARCHBiomedical researchNon-human researchCLINICAL&APPLIED DIAGNOSTIC&APPLIED INDUSTRIALClinical research,More regulatedClinical labs,Industrial$3.1bn in 20221 Majority

57、of customers today$3.1bn in 20221 Rapidly emerging:huge potential for growthLife Science Research Tools LSRTClinical Diagnostics and AppliedFoundation for 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,m

58、itigate,cure,or prevent any disease or condition.We continue to innovate in LSRT,and lock down in appliedFrom rapid innovation to rapid,applied insightsLife Science Research ProductsBetaRegistration Based EarlyAccessOpen Early AccessReleasedQ-LineApplied market and partner productsQFeature frozen pr

59、oductSoftware&consumable version support for at least 12-18 months Clearly defined,visible product update pathway andimplementation supportISO9001 with clear pathway to increase to 13485 by no laterthan 2026PromethION Q currentlyin developmentQQALocked for specific applicationSoftware&consumable ver

60、sion support for 24 months+Heavily developed withpartner assays in mindCE-IVD readyAAQQA1234 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.Register your

61、 interest hands off nanopore sequencingExtract,prepare,sequence,analyse all-in-onebenchtop deviceFlexibility to meet your needsMinIONTM or PromethIONTM 2 Solo on boardScalable and intuitiveMultiplex up to 48 samples with pre-programmed,sample-to-answer workflowsSimple data analysisOnboard compute an

62、d EPI2METM analysis workflows Benchtop device capable of sample extraction,library prep,sequencing,and data analysisSample to answerTurBOT 2023 Oxford Nanopore Technologies plc Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or

63、prevent any disease or condition.2024 Oxford Nanopore Technologies plc Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mitigate,cure,or prevent any disease or condition.OncologyHuman GeneticsInfectious DiseaseVet&AgBiopharma QCFood&EnvWe draw

64、 on a broad universe of potential partners and collaboratorsNanopore Research CommunityLargeCompaniesAnnounced Partnerships inClinical&Applied Industrial 2024 Oxford Nanopore Technologies plc.Oxford Nanopore Technologies products are not intended for use for health assessment or to diagnose,treat,mi

65、tigate,cure,or prevent any disease or condition.Key medium-term revenue driversFY23FY2630%underlying CC growth p.a.Robust innovation pipeline with frequent platform upgrades and product launchesExpanding,underpenetrated market opportunity coupled with unique features and benefits of Oxford Nanopores technology underpin growthIncreased penetration of LSRT clinical and applied industrial markets;expected to contribute 10-20%of LSRT revenue by FY26New customer acquisition and increased utilisation in S2 and S3 customer groups will be a key driver of growthEND